Physician profile
Lance Wallace
NPI 1538100128
$9,502.09
in general payments reported to CMS, 2019-2025
41 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,730 · 2020: $1,541 · 2021: $627 · 2022: $1,114 · 2023: $1,242 · 2024: $1,808 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,483 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,483.28 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,337.74 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,222.87 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Pfizer INC. | $1,042.23 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $933.85 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $769.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $595.83 | 2019-2025 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $478.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $370.86 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.28 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $270.87 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $217.51 | 2019-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $200.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $178.50 | 2021-2025 | Otezla, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $169.51 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $158.39 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.